Swiss Parenterals Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Swiss Parenterals Limited - overview
Established
1986
Location
Ahmedabad, Gujarat, India
Primary Industry
Pharmaceuticals
About
Based in Gujarat, India, and founded in 1986, Swiss Parenterals Limited, operates as a generic and specialty drug manufacturer and provider of machinery and infrastructure at the manufacturing units. In February 2024, Eris Lifesciences Limited, a portfolio company of ChrysCapital and Kuwait Investment Authority, agreed to acquire a 51% majority stake in Swiss Parenterals for INR 6. 37 billion. As of 2024, the company is led by its director, Naishadh Shah.
The company offers regular and complex dosage forms, catering to a wide range of medical needs. The company provides a range of injectables that include parenterals, inhaled anasthesia, ophthalmic and nasal, orals, semi-solids, nutritional (OTC), and many more. Following the February 2024 acquisition, the company plans to bolster the company's domestic presence with a new injectables-focused branded formulations business and enhance its reach in emerging markets.
Current Investors
Eris Lifesciences Limited
Primary Industry
Pharmaceuticals
Sub Industries
Medical Supplies, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.swiss.in/
Verticals
Manufacturing
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Swiss Parenterals Limited - timeline of key events
Swiss Parenterals Limited - financials
| Fiscal Year Ended | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|
| Revenue (USD) | 1,008,829,779 | 1,111,877,333 | 1,861,980,611 | - | - | - |
| % Revenue Growth (YoY) | - | 10.2% | 67.5% | - | - | - |
| EBITDA (USD) | 330,123,120 | 424,286,919 | 764,682,520 | - | - | - |
| Operating Income (USD) | 284,477,270 | 356,886,798 | 701,620,265 | - | - | - |
| Operating Margin | 28.2% | 32.1% | 37.7% | - | - | - |
| % EBITDA Margin | 32.7% | 38.2% | 41.1% | - | - | - |
| NET Income (USD) | 189,922,411 | 263,221,366 | 528,182,835 | - | - | - |
| % Net Margin | 18.8% | 23.7% | 28.4% | - | - | - |
Swiss Parenterals Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Swiss Parenterals Limited | - |
Displaying 1 - 1 of 1
Swiss Parenterals Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.